All In Biotech

Drug Trial Radar · NCT06028074

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation With Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GIM-122 as a Single Agent in Adult Subjects With Advanced Solid Malignancies

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

111

Planned (sponsor's estimate)

Start

Dec 12, 2023

Primary completion

Sep 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Georgiamune IncIndustry
Sponsor type
Industry
First posted
Sep 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.

Conditions

  • Advanced Solid Malignancies

Interventions

  • GIM122Drug

    GIM-122 administered IV once every 3 weeks or every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicities [DLT] with GIM-122Time frame: 18 months
  2. Maximum tolerated dose [MTD] of GIM-122Time frame: 18 months
  3. Recommended Phase 2 Dose [RP2D] of GIM-122Time frame: 18 Months
  4. Overall response rate (ORR) -Part B of the studyTime frame: 36 months
  5. Anti-tumor activity of GIM-122Time frame: 36 months
  6. Incidence and severity of AE / SAEs and tolerabilityTime frame: 36 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Institute

    Los Angeles, California · Recruiting

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UCLA Hematology/Oncology

    Los Angeles, California · Recruiting

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • Rutgers Cancer Institute of NJ

    New Brunswick, New Jersey · Recruiting

  • Tennessee Oncology, PLLC

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Baylor Sammons Cancer Center

    Dallas, Texas · Recruiting

  • NEXT Oncology Dallas

    Irving, Texas · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.